Tag: BIO HEA MTC

Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July

Synthego Solidly Positioned for Expansion & Growth REDWOOD CITY, Calif., June 26, 2025 /PRNewswire/ -- Synthego, a leading provider of CRISPR solutions, today confirmed...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could...

TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.

GMP TERBIUM-161 PRODUCT LAUNCHED BY TERTHERA BREDA, Netherlands, June 5, 2025 /PRNewswire/ -- TerThera B.V. has officially launched the world's first GMP-compliant Terbium-161 NCA, setting...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsBIO HEA MTC

InventHelp Inventor Develops New Dust Management System (TLS-837)

FortisBC to issue call for power to help meet energy demand in the Southern Interior

European savings and retirement services group Athora to acquire Pension Insurance Corporation Group

Tag: BIO HEA MTC

Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

TerThera reached GMP status for their Terbium-161 product, improving clinical access by meeting the highest quality standards.

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us